Carcinoma epidermoide cutáneo avanzado tratado con pembrolizumab
Open Access
- 1 July 2021
- journal article
- letter
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 112 (7) , 672-675
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Current evidence for safety and efficacy of anti–programmed cell-death 1 agents in the treatment of cutaneous squamous cell carcinoma: A systematic reviewJournal of the American Academy of Dermatology, 2020
- Inmunoterapia en cáncer cutáneo no melanomaActas Dermo-Sifiliograficas, 2019
- Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in EnglandJAMA Dermatology, 2019
- Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin CancerDermatologic Surgery, 2019
- Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis.Journal of Clinical Oncology, 2018
- Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC).Journal of Clinical Oncology, 2018
- Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With PembrolizumabJAMA Dermatology, 2017
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyFrontiers in Pharmacology, 2017
- Targeting regulatory T cells in tumor immunotherapyImmunology & Cell Biology, 2014